Adderall Dosing Guidelines
Start Adderall (amphetamine/dextroamphetamine) at 2.5 mg daily in children ages 3-5 years or 5 mg once or twice daily in children 6 years and older, titrating by 2.5-5 mg weekly until optimal response is achieved, with a maximum total daily dose of 40 mg. 1
Initial Dosing by Age Group
Children Ages 3-5 Years
- Starting dose: 2.5 mg daily 2, 1
- Titration: Increase by 2.5 mg at weekly intervals 2
- Administration: Given in the morning after breakfast and around noon after lunch for immediate-release formulations 2
Children Ages 6 Years and Older
- Starting dose: 5 mg once or twice daily 2, 1
- Titration: Increase by 2.5-5 mg weekly 2
- Special consideration: Children weighing less than 25 kg should not receive single doses greater than 10 mg 2
Adolescents (Ages 12-18)
- Starting dose: 5 mg once or twice daily 2
- Titration: Increase by 2.5-5 mg weekly 2
- Studies demonstrate efficacy up to 40 mg/day in adolescents with forced-dose titration 3
Maximum Dosing
The FDA-approved maximum total daily dose is 40 mg for amphetamines 2, 1. The Physician's Desk Reference states this limit, though expert consensus acknowledges that doses may occasionally exceed this in rare cases when lower doses prove inadequate 2. However, if the maximum recommended dose does not provide benefit, increasing the dose further is not recommended—consider switching medications or adding psychosocial interventions instead 2.
Formulation-Specific Considerations
Immediate-Release (IR) Formulations
- Dosed 2-3 times daily due to short duration of action 2
- First dose upon awakening, additional doses at 4-6 hour intervals 1
- Avoid late evening doses due to insomnia risk 1
Extended-Release (XR) Formulations
- Once-daily dosing with 12-hour duration of action 4, 5
- Rapid onset within 1.5 hours 5
- Bioavailability of Adderall XR 20 mg comparable to Adderall IR 10 mg twice daily 5
- Demonstrated efficacy in adolescents at doses of 10-40 mg/day 3
Pre-Treatment Requirements
Before initiating Adderall, obtain baseline blood pressure, pulse, height, and weight within a physical examination 2. This screening identifies:
- Malignant hypertension in children and adolescents
- Essential hypertension in adults
- Cardiac arrhythmias across all ages 2
Document prior treatments including medication names, dosages, duration, response, side effects, and compliance 2.
Monitoring Schedule
During Titration (2-4 weeks)
- Weekly contact by telephone or office visit 2
- Systematic assessment of target ADHD symptoms from parents and teachers 2
- Monitor for side effects: insomnia, anorexia, headaches, social withdrawal, tics, weight loss 2
Maintenance Phase
- Children: Annual vital sign checks during routine physical examination 2
- Adults: Quarterly blood pressure and pulse monitoring 2
- Monthly appointments until symptoms stabilized 2
- Weight measurement at each visit to objectively assess appetite suppression 2
Critical Safety Considerations
Cardiovascular Risks
Daily amphetamine use increases systolic blood pressure by 1.93 mmHg and diastolic blood pressure by 1.84 mmHg, with heart rate increasing by 3.71 beats per minute 6. These effects persist with long-term use (≥8 weeks) 6. Prolonged use has been associated with cardiomyopathy through mechanisms including oxidative stress, sympathetic overactivity, and direct myocardial toxicity 7.
Common Side Effects
Amphetamines produce greater problematic effects on appetite and sleep compared to methylphenidate, consistent with longer excretion half-lives 2. In adolescent trials, the most common adverse events were:
- Anorexia/decreased appetite: 35.6% vs 1.9% placebo 3
- Headache: 16.3% vs 22.2% placebo 3
- Insomnia: 12.0% vs 3.7% placebo 3
- Abdominal pain: 10.7% vs 1.9% placebo 3
- Weight loss: 9.4% vs 0% placebo 3
Withdrawal due to adverse effects occurs 2.69 times more frequently with amphetamines than placebo 6.
Contraindications
Absolute contraindications 2, 1:
- Previous sensitivity to stimulant medications
- Glaucoma
- Symptomatic cardiovascular disease
- Hyperthyroidism
- Hypertension
- Concurrent MAO inhibitor use
- Active psychotic disorder
- History of stimulant abuse (unless in controlled setting)
Pharmacokinetic Considerations
- Absorption: Rapid with high bioavailability 8
- Time to peak (Tmax): IR formulations 2-3 hours 8
- Half-life: Children ~7 hours; Adults ~10-12 hours 8
- Body weight is a fundamental determinant of plasma concentrations 8
- Dose-proportional pharmacokinetics across therapeutic range 8
Clinical Pearls
Approximately 43% of responders show preferential response to only one stimulant formulation 9, suggesting that if amphetamine/dextroamphetamine proves inadequate, switching to methylphenidate (or vice versa) is reasonable before abandoning stimulant therapy entirely.
Dose level, rather than stimulant class, is strongly related to medication response 9, emphasizing the importance of adequate titration to maximum tolerated doses before declaring treatment failure.
For patients with high baseline ADHD severity, all dose levels (10-40 mg) showed statistically significant improvement, while those with low baseline severity required at least 20 mg for significant benefit 3.